HIGHLIGHTS
- who: Robert J. Motzer from the (UNIVERSITY) have published the article: Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial, in the Journal: (JOURNAL) of 22/09/2022
- what: The authors report a comprehensive genomic and transcriptomic analysis of tumor samples from 171 patients at high risk for recurrent renal cell carcinoma post nephrectomy from the S-TRAC trial (NCT00375674). The authors focused on the sunitinib treatment arm of the S-TRAC study to identify molecular characteristic that might associate with the resistance to anti-angiogenesis adjuvant treatment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.